Torsten Neuefeind

Proteros is a biotech company focused on enabling lead discovery for challenging targets. Proteros has established a profitable discovery service business with a best-in-class enabling technology platform for structure accelerated lead discovery. Their track record is proven by an outstanding project success rate. Proteros’ proprietary pipelineincludes highly disease relevant target classes such as kinases, epigenetic targets and GPCRs. Their success is built on unique know how and expertise in understanding the role of protein structures involved in protein and small molecule interactions that are responsible for the pathogenesis of many diseases.